Mike West

Photo: Courtesy of Advanced Cell Technology In these days of rampant science phobia, a researcher associated with human cloning risks being linked to the few renegade scientists claiming to already have done the deed. Mike West's quest as president and CEO of Advanced Cell Technology (ACT) in Worcester, Mass., is not to clone dinosaurs or replace children, but to customize cells to rebuild degenerating or injured human tissue. The company's late 2001 announcement1 that it had created a human

Written byRicki Lewis
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

In these days of rampant science phobia, a researcher associated with human cloning risks being linked to the few renegade scientists claiming to already have done the deed. Mike West's quest as president and CEO of Advanced Cell Technology (ACT) in Worcester, Mass., is not to clone dinosaurs or replace children, but to customize cells to rebuild degenerating or injured human tissue.

The company's late 2001 announcement1 that it had created a human embryo by transfer of a somatic cell nucleus to an enucleated egg attracted media attention, including a Business Week profile of West headlined "Cloning: Huckster or Hero?" No mention was made of the company's contributions to basic developmental biology2-4 or pro bono work on endangered species.5 West tries not to let it get to him. "I have a thick skin, but it hurts. There are days that I go home and think, 'Why don't I just take ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies